OncoSec's President and CEO Explains His Firm's Ambitious List of Milestones for 2012

(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 02/02/12 -- In an exclusive interview with BioMedReports, Punit Dhillon, the President and CEO of OncoSec Medical Inc. (OTCBB: ONCS), explains some of the reasons why investors may be taking positions in the company after a slow but steady sell-off in the market.

In March of 2011, Mr. Dhillon became president and chief executive officer after co-founding the firm and as we discuss in his candid interview, OncoSec is currently initiating three Phase 2 clinical trials in metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. All three of these trials are being held under a physician Investigational New Drug (IND) application. This regulatory path has allowed OncoSec to enter the clinic and quickly obtain clinical catalysts. The Company will leverage data from these studies to initiate our own sponsor IND in 2012.

The full exclusive Q&A is available now at:



In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:



News developments and live healthcare sector updates are available constantly via twitter at: .

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com





Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 02.02.2012 - 13:35 Uhr
Sprache: Deutsch
News-ID 110383
Anzahl Zeichen: 0

contact information:
Town:

LOS ANGELES, CA

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 284 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"OncoSec's President and CEO Explains His Firm's Ambitious List of Milestones for 2012"
steht unter der journalistisch-redaktionellen Verantwortung von

BioMedReports (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead ...

LOS ANGELES, CA -- (Marketwired) -- 11/06/13 -- In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed bioph ...

Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" ...

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- With shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (NYSE MKT: CVM) who last provide ...

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D. ...

LOS ANGELES, CA -- (Marketwired) -- 07/23/13 -- It has been over a year since Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talk ...

Alle Meldungen von BioMedReports